Feature | February 18, 2014

Neovasc Announces Successful Human Implant of Tiara Transcatheter Mitral Valve

Neovasc Tiara transcatheter mitral valve heart repair clinical trial study

February 18, 2014 — Neovasc Inc. announced that a first-in-human implantation of its Tiara transcatheter mitral valve was successfully performed Jan. 30 by physicians at St. Paul’s Hospital in Vancouver, BC. The transapical procedure resulted in the elimination of mitral regurgitation (MR) and significantly improved heart function in the patient, without the need for cardiac bypass support and with no procedural complications. 

The implantation was conducted by Anson Cheung, professor of surgery and director of cardiac transplant, and John Webb, director of interventional cardiology at St. Paul ’s Hospital. They were supported by Stefan Verheye, senior interventional cardiologist at the Antwerp Cardiovascular Center / ZNA Middelheim, Belgium and Shmuel Banai, medical director of Neovasc and director of interventional cardiology at Tel Aviv Medical Center, Israel.

“This 73 year-old male patient had severe functional mitral regurgitation and was considered an extremely high risk candidate for conventional valve repair or replacement surgery,” Cheung said. “The transapical implantation of the Tiara valve was completed quickly and without complications. It resulted in a well-functioning bioprosthetic valve with no significant paravalvular leak or residual MR.”

Tiara is a self-expanding mitral bioprosthesis specifically designed to treat mitral valve regurgitation, a serious and poorly served condition that requires development of highly specialized devices to address the complex mitral anatomy. Significant mitral regurgitation can lead to heart failure and death. Conventional surgical treatments are only appropriate for about half of the estimated four million MR patients in the United States.

Tiara is implanted in the heart using a minimally-invasive, transcatheter approach and is designed to replace the diseased native mitral valve without the need for open heart surgery or use of a cardiac bypass machine.

For more information: www.neovasc.com

Related Content

News | Heart Valve Repair| November 23, 2015
NaviGate Cardiac Structures Inc. (NCSI) announced that a first-in-human implant of its catheter-guided, mitral-valved...
protein reprogramming, Stem Cells Translational Medicine, cardiac progenitor cells, CPCs, regenerative therapies
News | Stem Cell Therapies| November 13, 2015
A new study appearing in STEM CELLS Translational Medicine (SCTM) describes a highly efficient, protein-based method...
angina, abnormal heart blood flow, female-pattern heart disease, Cedars-Sinai Heart Institute study, AHA Scientific Sessions
News | Cardiac Diagnostics| November 13, 2015
Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, a new Cedars-Sinai Heart Institute...
News | Antiplatelet and Anticoagulation Therapies| November 12, 2015
Preventing blood clots with drugs such as heparin has become a common practice for fighting some heart and lung...
pharmacist-physician collaboration, high blood pressure control, minority and low-income populations
News | Hypertension| November 12, 2015
November 12, 2015 — A pharmacist-physician collaborative effort to control blood pressure among a diverse group of pa
Neovasc, Tiara, transcatheter mitral valve, TMVR

The Neovasc Tiara transcatheter mitral valve is currently being tested in U.S. and international clinical trials. 

Feature | Heart Valve Repair| November 12, 2015 | Dave Fornell
The advent of transcatheter valve repair and replacement technologies is one of those rare instances where there is a
obese kids, eight years old, heart disease, MRI, Linyuan Jing
News | Cardiac Diagnostics| November 11, 2015
Imaging tests of obese children — some as young as 8 years old — showed signs of significant heart disease and heart...
Pradaxa, warfarin, safety and effectiveness, NVAF, non-valvular atrial fibrillation, clinical trial, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies| November 11, 2015
Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new interim analysis from a...
SALUS trial, Direct Flow Medical TAVR device, Medtronic CoreValve, PinnacleHealth CardioVascular Institute

Image courtesy of Direct Flow Medical

News | Heart Valve Repair| November 10, 2015
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a randomized trial studying a new...
Overlay Init